Mintz Advises Dare Bioscience in $22M Non-Dilutive Strategic Royalty, Revenue Interest Financing
May 14, 2024
May 14, 2024
BOSTON, Massachusetts, May 14 -- Mintz, a law firm, issued the following news release:
Mintz advised Dare Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company focused on women's health, in a $22 million non-dilutive strategic royalty and revenue interest financing transaction with XOMA (US) LLC.
The transaction, which closed April 30, 2024, involved the sale of (a) the remaining royalties and potential milestones based on net sales of XACIATO payable to Dar . . .
Mintz advised Dare Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company focused on women's health, in a $22 million non-dilutive strategic royalty and revenue interest financing transaction with XOMA (US) LLC.
The transaction, which closed April 30, 2024, involved the sale of (a) the remaining royalties and potential milestones based on net sales of XACIATO payable to Dar . . .